AVT 02

Drug Profile

AVT 02

Alternative Names: AVT-02 UE

Latest Information Update: 30 Nov 2011

Price : $50

At a glance

  • Originator University of Gottingen
  • Developer DOLTHERA
  • Class Anti-inflammatories; Antipsoriatics; Oligonucleotides
  • Mechanism of Action STAT1 transcription factor inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 31 Mar 2011 Discontinued - Phase-II for Psoriasis in Europe (Topical)
  • 06 Jan 2010 AnGes MG terminates its licence for AVT 02 in respiratory and dermal indications in Asia
  • 10 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Psoriasis released by Avontec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top